Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies
Shots:
- iPS Academia Japan to receive payments from Thyas. Thyas to get exclusive patent rights for production and usage of iPS cell-derived T cells- with non-exclusive rights for its development and commercialization
- The focus of the agreement is to develop tumor-specific or virus-specific T cells using iPS’ technology- with proliferative capacity and potent killing capability for cancer and infectious diseases
- Induced Pluripotent Stem (iPS) cells have purity- functionality and are KIR (Killer-immunoglobulin receptors) negative used for killing or targeting cancer or tumor cells
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
